These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16215351)

  • 1. Ovarian hyperstimulation syndrome.
    Budev MM; Arroliga AC; Falcone T
    Crit Care Med; 2005 Oct; 33(10 Suppl):S301-6. PubMed ID: 16215351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian hyperstimulation syndrome: A review for emergency clinicians.
    Timmons D; Montrief T; Koyfman A; Long B
    Am J Emerg Med; 2019 Aug; 37(8):1577-1584. PubMed ID: 31097257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian hyperstimulation syndrome.
    Avecillas JF; Falcone T; Arroliga AC
    Crit Care Clin; 2004 Oct; 20(4):679-95, ix. PubMed ID: 15388196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials.
    Humaidan P; Nelson SM; Devroey P; Coddington CC; Schwartz LB; Gordon K; Frattarelli JL; Tarlatzis BC; Fatemi HM; Lutjen P; Stegmann BJ
    Hum Reprod; 2016 Sep; 31(9):1997-2004. PubMed ID: 27343272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.
    Delvigne A; Rozenberg S
    Hum Reprod Update; 2002; 8(6):559-77. PubMed ID: 12498425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for recovery time in patients suffering from severe OHSS.
    Nouri K; Tempfer CB; Lenart C; Windischbauer L; Walch K; Promberger R; Ott J
    Reprod Biol Endocrinol; 2014 Jul; 12():59. PubMed ID: 24996451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intensive care for ovarian hyperstimulation syndrome].
    Shifman EM; Pogodin OK; Gumeniuk EG; Pogodin OO
    Anesteziol Reanimatol; 2007; (4):77-81. PubMed ID: 17929495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).
    Delvigne A; Rozenberg S
    Hum Reprod Update; 2003; 9(1):77-96. PubMed ID: 12638783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian hyperstimulation syndrome prevention strategies: cryopreservation of all embryos.
    D'Angelo A
    Semin Reprod Med; 2010 Nov; 28(6):513-8. PubMed ID: 21082511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory evaluation of hospitalized patients with severe ovarian hyperstimulation syndrome.
    Cunha-Filho JS; Samama M; Fanchin R; Righini C; Kadoch IJ; Frydman R; Olivennes F
    Reprod Biomed Online; 2003 Jun; 6(4):448-51. PubMed ID: 12831592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian hyperstimulation syndrome: facts and fallacies.
    Beerendonk CC; van Dop PA; Braat DD; Merkus JM
    Obstet Gynecol Surv; 1998 Jul; 53(7):439-49. PubMed ID: 9662730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ovarian Hyperstimulation Syndrome.
    Blumenfeld Z
    Vitam Horm; 2018; 107():423-451. PubMed ID: 29544639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian hyperstimulation syndrome management strategies: where are we going?
    Eskew AM; Omurtag KR
    Minerva Endocrinol; 2018 Mar; 43(1):50-56. PubMed ID: 28322539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.
    Luke B; Brown MB; Morbeck DE; Hudson SB; Coddington CC; Stern JE
    Fertil Steril; 2010 Sep; 94(4):1399-1404. PubMed ID: 19591989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
    Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.